Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kairos Pharma, Ltd. ( (KAPA) ) has issued an update.
On September 18, 2025, Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV105 in patients with metastatic castration-resistant prostate cancer. The trial showed a median progression-free survival of over 13 months, significantly exceeding the standard hormone therapy benchmarks. The company hosted a virtual event to discuss these findings, highlighting the potential of ENV105 to address the unmet need for effective treatments in prostate cancer resistant to hormone therapies.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd., based in Los Angeles, California, is a clinical-stage biopharmaceutical company focused on oncology therapeutics. The company aims to overcome drug resistance and immune suppression in cancer through structural biology. Its lead candidate, ENV105, targets CD105, a protein linked to resistance in cancer treatments, and is currently in Phase 2 clinical trials for castration-resistant prostate cancer and Phase 1 trials for lung cancer.
Average Trading Volume: 5,175,783
Technical Sentiment Signal: Strong Buy
See more insights into KAPA stock on TipRanks’ Stock Analysis page.